In recent years it has become clear that genetics plays a key role in the development of Parkinson’s. By understanding genetic pathways, the hope is that a novel drug to prevent or slow down Parkinson’s development can be produced. One of the most common genes implicated in Parkinson’s is glucocerebrosidase (GBA). About 10% of people with Parkinson’s in the UK carry a mutation in this gene.
Dr. Stephen Mullin holds a clinical lectureship in Neurology at The Faculty of Medicine and Dentistry at Plymouth University. In this presentation he described how the GBA gene causes Parkinson’s, outlined some exciting recent advances in drug development, and fielded questions from the audience.